natgillin/translations-raw huggingface dataset:
The composition for use according to claim 2, wherein the DIGRA has Formula II or III wherein R4 and R5 are independently selected from the group consisting of unsubstituted C1-C10 linear or branched alkyl groups, substituted C1-C10 linear or branched alkyl groups, unsubstituted C3-C10 cyclic alkyl groups, and substituted C3-C10 cyclic alkyl groups. 
Pripravak za uporabu prema patentnom zahtjevu 2, naznačen time da DIGRA ima formulu II ili III (I) (lil) gdje su R* i R> nezavisno izabrani iz skupine koja sadrži nesupstituiranu C,-C,g linearnu ili razgranatu alkil skupinu, supstituiranu Ci-Cyo_ linearnu ili razgranatu alkil skupinu, nesupstituiranu C3-Cyg cikličnu alkil skupinu i supstituiranu C3-Cio cikličnu alkil skupinu.
For example, as shown in Figure 13, paclitaxel of Formula 1 (where R1=R2=Ph; R7=CH3 in generalized formula A of Scheme 1) is first protected at the 2'-hydroxyl with a hydroxyl protecting group such as tert -butyldimethylsilyl (TBDMS). 
Na primjer, kao što je prikazano na slici 13, paklitaksel formule 1 (gdje Ri=R>=Ph; R;=CH; u općoj formuli A iz sheme 1) je najprije zaštićen na 2'-hidroksilu s hidroksil zaštitnom skupinom kao što je tert-butildimetilsilil (TBDMS).
The invention aims to remedy these disadvantages by providing a sanding element with a much longer life than the present sanding elements, while it allows for finishing a workpiece almost to perfection in a very fast manner, as a result of which the use of two different discs is no longer necessary. 
Ovaj izum ima za cilj da se poprave ovi nedostaci i on osigurava element za brušenje s mnogo duljom životnom dobi nego što je imaju sadašnji elementi za brušenje, dok isto tako omogućava da se komad koji se obrađuje završno obradi do savršenstva na vrlo brz način, a kao rezultat toge je to, da više nisu potrebna dva različita diska.
The composition of claim 1, wherein said regulatory RNA targets the RNA transcript encoding a protein that contributes to drug resistance, apoptosis resistance or neoplasticity. 
Sastav zahtjeva 1, time naznačeno da regulatorna RNK posebno ometa ekspresiju proteina koji pridonosi stvaranju otpornosti na ljekove.
A nasal spray device as claimed in claim 1, wherein the active Ingredient is beclomethasone dipropionate, the propellant is selected from P134a, P227 or mixtures thereof, or other pressurised gases, and the co-solvent is present and is anhydrous ethanol. 
Nazalni raspršivač za nos sukladno bilo kojem prethodnom zahtjevu, pri čemu je ko-otapalo etanol ili propilen glikol, a prvenstveno etanol, te najpoželjnije anhidrirani etanol. Nazalni raspršivač za nos sukladno bilo kojem prethodnom zahtjevu, pri čemu je aktivni sastojak beklometazon dipropionat, i prisutan je ko-otapalo, a to je anhidrirani etanol.
In a first aspect the invention provides a method for the quantification of a vaccine strain of Marek's Disease Virus Serotype-1 (MDV-1) in a sample from a bird, comprising the steps of: 
HR P20150308 T1 PATENTNI ZAHTJEVI Postupak kvantificiranja cjepivnog soja virusa Marekove bolesti serotip-1 (MDV-1) u uzorku iz ptice, naznačen time što se sastoji u koracima:
allowing spontaneous nucleation to occur; 
(ili) dozvoljavanje pojave spontane nukleacije;
The coating composition according to claim 26, wherein the poly(oxyalkylene)-modified polysiloxane is a polysiloxane having incorporated in the backbone thereof poly(oxyalkylene) chains. 
Smjesa za premaz prema patentnom zahtjevu 26, naznačena time da je poli(oksialkilen)-modificirani polisiloksan zapravo polisiloksan koji u svojoj srži ima ugrađene poli(oksialkilenske) lance.
subjects having a serum cholesterol level of at least 200 mg/dL; 
(ii) subjekti koji imaju razinu kolesterola u serumu od barem 200 mg/dI;
“4- to 10-membered heterocyclic group containing at least one ring heteroatom selected from the group consisting of nitrogen, oxygen and sulphur”, as used herein, may be monocyclic or bicyclic, e.g., furan, tetrahydrofuran, pyrrole, pyrrolidine, pyrazole, imidazole, triazole, isotriazole, tetrazole, thiadiazole, isothiazole, oxadiazole, pyridine, oxazole, isoxazole, pyrazine, pyridazine, pyrimidine, piperidine, piperazine, morpholine, triazine, oxazine, thiazole, quinoline, isoquinoline, benzothiophene, benzoxazole, benzisoxazole, benzothiazole, benzisothiazole, benzofuran, indole, indazole or benzimidazole. 
"4- do 10-člana heterociklička skupina koja sadrži najmanje jedan heteroatom u prstenu odabran između dušika, kisika 1 sumpora", kako se ovdje rabi, može biti monociklička ili biciklička skupina, npr. furan, tetrahidrofuran, pirol, pirolidin, pirazol, imidazol, triazol, izotriazol, tetrazol, tiadiazol, izotiazol, oksadiazol, piridin, oksazol, izoksazol, pirazin, piridazin, pirimidin, piperidin, piperazin, morfolin, triazin, oksazin, tiazol, kinolin, izokinolin, benzotiofen, benzoksazol, benzisoksazol, benzotiazol, benzizotiazol, benzofuran, indol, indazol ili benzimidazol.
encrypting a first communication message, with the symmetric-key, to an encrypted first communication message; and 
kodiranje (520) prve komunikacijske poruke, sa simetričnim ključem, u kodiranu prvu komunikacijsku poruku; i
In Vivo Assay 
Ispitivanje in vivo
deprotecting protected glatiramer acetate with a solution of hydrobromic acid in acetic acid, the solution comprises less than 0.5% of free bromine and less than 1000 ppm of metal ion impurities, to form trifluoroacetyl glatiramer acetate; 
skidanje zaštite sa zaštićenog glatiramer acetata otopinom bromovodične kiseline u octenoj kiselini, koja je otopina prethodno obrađena hvatačem broma radi uklanjanja slobodnog broma, da bi se formirao trifluoracetil glatiramer acetat;
A compound of the formula I, wherein 
Spoj s formulom I, [image] naznačen time da
Process for producing virgin olive oil, the process comprising the steps of: 
Proces za proizvodnju djevičanskog maslinovog ulja, proces koji sadrži korake:
A method of treating cancer in a patient in need thereof comprising administering to the patient a therapeutically effective amount of the compound of claim 1, in the form of a base, an enantiomer, a diastereomer, or an acid addition salt. The method of claim 18, wherein the cancer is selected from the group consisting of carcinomas which have a metabolism dependent on oxidative phosphorylation, overexpressing c-Myc tumor, well to medium differentiated tumors, cancers which induce primary lymph node and lung metastases, and early grades of cancers described to present hypoxic regions during their development and metabolic adaptation (glycolytic shift). 
Spoj za uporabu prema zahtjevu 19, naznačen time što je rak odabran od karcinoma koji imaju metabolizam ovisan o oksidativnoj fosforilaciji, kao što su tumori pluća, te naročito karcinomi pluća ne-malih stanica, tumori dojke ovisni o hormonima, tumori jajnika, hepatokarcinomi, gastrointestinalni tumori, tumori gušterače, i tumori debelog crijeva, tumor koji prekomjerno eksprimira c-Myc kao što su limfomi, rak dojke ili debelog crijeva,, dobro do srednje diferencirani tumori, karcinomi koji induciraju primarni limfni čvor i metastaze pluća, rane vrste karcinoma za koje je opisano da imaju hipoksične regije tijekom njihova razvoja i metaboličku prilagodbu (glikolitička promjena) kao što su melanomi, gliomi, karcinomi glave i vrata i leukemije.
centrifuging the precipitated supernatant to obtain a pellet; 
-centrifugiranja istaloženog supernatanta kako bi se dobio pelet;
The method of claim 9, wherein the second therapeutic agent is selected from ritonavir, efavirenz, didanosine, tenofovir disoproxil, nelfinavir mesilate, amprenavir, raltegravir potassium, saquinavir, lopinavir, nevirapine, emtricitabine, abacavir, lamivudine, zidovudine, maraviroc, stavudine, darunavir, fosamprenavir, vicriviroc, a pharmaceutically acceptable salt of any of the foregoing, and combinations thereof. 
Spoj ili kompozicija prema zahtjevu 16, gdje se drugo terapeutsko sredstvo bira od ritonavira, efavirenca, didanozina, tenofovir dizoproksila, nelfinavir mesilata, amprenavira, kalij raltegravira, sakvinavira, lopinavira, nevirapina, emtricitabina, abakavira, lamivudina, zidovudina, maraviroka, stavudina, darunavira, fosamprenavira, vicriviroca, farmaceutski prihvatljive soli bilo kojeg od naprijed navedenih i njihovih kombinacija.
A compound or a pharmaceutically acceptable salt thereof of any one of claims 1 to 12 or pharmaceutical composition of claim 13 for use in treating a cancer associated with PKM2 activity in a subject in need thereof. 
Tvar ili farmaceutski sastav iz bilo kojeg od patentnih zahtjeva 1 do 38 za uporabu u liječenju raka povezanog s PKM2 aktivnosti u potrebitog subjekta.
The polypeptide of claim 1, wherein at least one of the soluble TRAIL domains has an N-terminal sequence which starts at amino acid Gln120, Arg121, or Val122 of human TRAIL (SEQ ID NO: 10), and the Arg121 is optionally replaced by a neutral amino acid of serine or glycine. The polypeptide of claim 3, wherein at least one of the soluble TRAIL domains has an N-terminal sequence selected from 
Polipeptid prema bilo kojem od zahtjeva 1-2 pri kojem je najmanje jedna od topljivih citokinskih domena iz TNF obitelji, naročito najmanje jedna topljiva citokinska domena TNF obitelji (iii) i (v), topljiva TRAIL domena s N-terminalnim slijedom koji počinje između amino kiseline Gln120 1 Val122 od humane TRAIL i pri čemu Arg121 može biti zamijenjena neutralnom aminokiselinom, primjerice Ser ili Gly.
coupling a compound of formula (II) with a compound of formula (IV) in a suitable solvent, in the presence of a coupling agent, and optionally in the presence of an activating agent of the coupling agent, or 
R! (V) uz naknadno odcjepljenje, u istoj reakcijskoj smjesi, ketalne ili acetalne skupine u spoju formule (V), u pogodnom otapalu, čime se dobije spoj formule (VI)
the transdermal patch system and the adhesive layer is free or essentially free of any drug; or 
(1) < transdermalni sustav flastera 1 ljepljivi sloj je bez ili suštinski bez bilo kojeg lijeka; ili
The method according to claim 29, wherein said reinforcement element is applied directly to the lower edge of the membrane after the association of the membrane with the upper. 
Postupak u skladu s patentnim zahtjevom 33, naznačen time, da se navedeni element za ojačavanje (651) postavlja izravno na donji rub membrane nakon spajanja membrane s gornjištem.
The amounts are highly variable, preferably 5 to 95% by weight of latently hydraulic and/or pozzolanic material and 5 to 95% by weight of ternesite clinker are added. Preferred are 30 to 85% by weight of latently hydraulic and/or pozzolanic material and 15 to 70% by weight of ternesite, more preferably 40 to 80% by weight of latently hydraulic material and 20 to 60% by weight of ternesite, wherein the values are relative to the total quantity of binder, and the portions in combination with those of the remaining binder components add up to 100%. 
Postupak sukladno bilo kojem od zahtjeva 1 do 7, naznačen time što, uz C5925 i C4A,Fq.9)3$, klinker sadrži 0 do 30% po težini Cx(A,F(1.y)), s y opsega od 0.2 do 0.8, 0 do 20% po težini reaktivnih aluminata, 0 do 25% po težini periklasa (M), i O do 30% po težini sekundarne faze, relativno ukupnoj količini klinkera sa sadržajem sekundarne faze do 100%.
6C, a door 201 in housing 200 allows access to pump 40, compressor 50, and other components (e.g. solenoids, valves, tubing), . 
Kako je prikazano na slici 6C, vrata 201 na kućištu 200 omogućuju pristup pumpi 40, kompresoru 50, i drugim komponentama (na primjer solenoidima, ventilima, cjevovodima).
A pharmaceutical composition according to claim 9 in the form of a lyophilized powder or a frozen solution. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 12, naznačen time što je u obliku liofiliziranog praha ili smrznute otopine.
In this embodiment, saving internet addresses in the storage folder C comprises a transfer of the corresponding multimedia content item R 1 -RN from the servers 50 - 54 to the memory of the client 1 so as to allow displaying in “off-line” mode. 
Metoda prema patentnom zahtjevu 1, naznačena time da navedeni korak učitavanja navedenih internetskih adresa uključuje korak prenošenja navedenih multimedijalnih sadržaja (R1,..., RN) s navedenog poslužitelja (50-54) u memoriju navedenog korisnika (1).
wherein A is a ring selected from: 
Spoj formule: pri čemu je A prsten odabran od:
n is independently 0 or 1; and wherein said first polypeptide chain comprises an amino acid sequence of SEQ ID NO: 212; wherein said second polypeptide chain comprises an amino acid sequence of SEQ ID NO: 215; and wherein the binding protein binds human IL-1B and human IL-1a. 
n je neovisno 0 ili 1; i pri čemu navedeni prvi polipeptidni lanac sadrži amino kiselinsku sekvencu iz SEQ ID NO: 212; pri čemu navedeni drugi polipeptidni lanac sadrži amino kiselinsku sekvencu iz SEQ ID NO: 215; i pri čemu vezujući protein veže ljudski IL-1B i ljudski IL-1a.
R1, R2 and R3 are members independently selected from substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; 
, R2 i R3 su članovi neovisno odabrani od supstituiranog ili nesupstituiranog arila, i supstituiranog ili nesupstituiranog heteroarila;
The method of claim 1, wherein the salt of the compound of Formula (I) comprises an tribenzenesulfonate salt. 
Sol spoja formule (I) prema patentnom zahtjevu 1 pri čemu je sol adiciona sol kiseline.
The composition according to claim 1, characterised in that said composition is a coating composition for solid oral formulations in the form of tablets, capsules, pellets, granules and/or microgranules. 
Obložena čvrsta oralna formulacija u skladu s patentnim zahtjevom 20, naznačena time što je u obliku tableta, kapsula, peleta, granula i/ili mikrogranula.
wherein the form is crystalline Compound I-1 anhydrous form A. 
pri čemu je oblik kristalni spoj I-1 • hidrat I;
A device as claimed in one or more of the preceding claims, characterized in that means are provided for compressing or aspirating the fluid component and/or the solid component of fat into or from the washing chamber (101) of the washing and separating container (1) and/or the reducing chamber (201) of the size reducing container (2). 
Uređaj kao što je navedeno u jednom ili više prethodnih patentnih zahtjeva, naznačen time da su osigurana sredstva za kompresiju ili aspiraciju tekuće komponente i/ili čvrste komponente masti u ili iz komore za pranje (101) kontejnera za pranje i odvajanje (1) i/ili komore (201) za smanjivanje kontejnera (2) za smanjivanje veličine.
Figures 7a and 7b show schematically a dispensing valve 30 for the dispensing assembly according to the invention. 
Slike 7a i 7b prikazuju shematski ventil za točenje 30 koji se koristi u sklopu za točenje prema izumu.
The methanol is removed in vacuo and the resulting white suspension is extracted with chloroform (3 x 20 ml), dried (MgSO4) and concentrated in vacuo to yield a white powder which is dried under high vacuum to yield the titled product. 
Metanol se odstrani u vakuumu i dobivenu bijelu suspenziju se ekstrahira s kloroformom (3 x 20 ml), osuši (MgSOxy) i koncentrira u vakuumu, čime se dobije bijeli prah koji se osuši pod visokim vakuumom, čime se dobije naslovni proizvod.
represents Lys wherein the -NH2 side chain group is functionalized with a group -Z-C(O)R5, wherein Z represents a group selected from YE, YE-YE, AEEAc-AEEAc-YE and AEEAc-AEEAc-AEEAc and R5 represents a group selected from pentadecanyl or heptadecanyl. 
predstavlja Lys pri čemu je skupina -NH2 bočnog lanca funkcionalizirana sa skupinom -Z-C(O)R5, pri čemu Z predstavlja skupinu odabranu od YE, YE-YE, AEEAc-AEEAc-YE i AEEAc-AEEAc-AEEAc i predstavlja skupinu odabranu od pentadekanila ili heptadekanila.
The agonist for use according to claim 1 for administration with a therapeutically effective amount of at least one other active agent selected from antibacterial agents, antiparasitic agents, antifungal agents, anti-inflammatory agents, antihistamines, anti-pruriginous agents, anesthetics, antiviral agents, keratolytic agents, anti free-radical agents, antioxidants, vitamin K, vitamin E, vitamin C, vitamin A, superoxide dismutase derivatives of plants, sesquiterpene lactones, antiseborrheic agents, antidandruff agents, antiacne agents, sunscreens and sun blocking agents, active agents which modify at least one or cutaneous differentiation, proliferation, and pigmentation, including but not limited to tretinoin, retinol, retinal, alpha hydroxyl acids, beta hydroxyl acids, and combinations thereof. 
Agonist za uporabu u skladu sa zahtjevom 1, naznačen time što se primjenjuje s terapeutski učinkovitom količinom najmanje jednog drugog aktivnog sredstva koje je odabrano od antibakterijskih sredstava, antiparazitskih sredstava, antifungalnih sredstava, protuupalnih sredstava, antihistaminika, sredstava protiv svrbeža, anestetika, antivirusnih sredstava, keratolitičkih sredstava, sredstava protiv slobodnih radikala, antioksidanata, vitamina K, vitamina E, vitamina C, vitamina A, derivati superoksid dismutaze biljaka, seskviterpenski laktoni, sredstva protiv seboreje, sredstva protiv prhuti, sredstva protiv akni, sredstava za zaštitu od sunca i sredstava za blokiranje sunca, aktivnih sredstava koja modificiraju najmanje jednu od kožnih diferencijacija, proliferaciju i pigmentaciju, uključujući ali ne ograničavajući se na tretinoin, retinol, retinal, alfa hidroksilne kiseline, beta hidroksilne kiseline, te njihove kombinacije.
Suitably substituted methyl 4-chlorocarbonylbenzoates were either commercially available or prepared by chlorination of the corresponding carboxylic acids with oxalylchloride or sulfonyl chloride, and were coupled with 2-amino thiazole in a suitable solvent such as 1,2-dichloroethane in the presence of a suitable base such as pyridine, at a suitable temperature between 20-60 °C. The products were then saponified to the corresponding carboxylates by procedures known to chemists skilled in the art, such as treatment with 2M NaOH (aq.) at a suitable temperature such as room temperature in the presence of a suitable organic co-solvent such as THF, followed by acidification to yield the carboxylic acid products. Experimental Section 
Prikladno supstituirani metil 4-klorokarbonilbenzoati su ili uobičajeno dostupni ili se mogu pripraviti kloriranjem odgovarajućih karboksilnih kiselina s oksalilkloridom ili sulfonil kloridom, i gdje se spajaju s prikladnom supstituiranim 2-amino tiazolom u odgovarajućem otapalu poput 1,2-dikloroetana u prisutnosti prikladne baze poput piridina, na prikladnoj temperaturi između 20-60 "C. Produkt se potom saponificira do odgovarajućeg karboksilata postupcima poznatim osobama koje se bave tim dijelom, kao što je postupak tretiranja s 2M NaOH (aq), na odgovarajućoj temperaturi, poput sobne temperature u prisutnosti prikladnog organskog kootapala kao što je THF, praćeno zakiseljavanjem kako bi se dobili produkti karboksilne kiseline.
A unit dosage form, wet granulation formulation, roller compaction formulation or direct compression formulation according to claim 9 wherein the compound of Formula (I) is in the form of Formula (II): 
Jedinični oblik doziranja, formulacija vlažne granulacije, formulacija za sabijanje valjkom ili formulacija za izravnu kompresiju prema zahtjevu 9 naznačen time što je spoj s Formulom (I) u obliku Formula (II): of" LIJ
An expression vector containing the nucleic acid molecule of claim 1 . 
Vektor, naznačen time, da sadrži molekulu nukleinske kiseline prema zahtjevu 4.
The composition of clause 15 in which the pH value of the composition is range from 7.0 to 8.0. The composition of clause 15 wherein the cyclodextrin is present at a concentration from 0.5% to 40% weight/volume. 
Sastav prema zahtjevu 11, naznačeno time da je ciklodekstrin prisutan u koncentraciji od 0,5% do 40% masa/volumen, poželjno u koncentraciji od 2,5% do 20% masa/volumen.
The composition of claim 6, wherein the Spy0269 antigen comprises SEQ ID NO:177. 
Pripravak u skladu s patentnim zahtjevom 6, naznačen time što Spy0269 antigen sadrži SEQ ID NO:177.
is selected from the group consisting of phenyl optionally substituted with methoxy or *1 to 3 independently selected chloro or fluoro substituents; pyrazol-4-yl optionally substituted with 1 to 3 methyl or ethyl groups; imidazolyl optionally substituted with 1 or 2 methyl or ethyl; pyridyl optionally substituted with fluoro or chloro; and thienyl; 
R1 se bira iz skupine koju čine fenil, izborno supstituiran s metoksi ili 1 do 3 neovisno odabrana supstituenta, klora ili fluora; pirazol-4-il, izborno supstituiran s 1 do 3 metilne ili etilne skupine; imidazolil, izborno supstituiran s 1 ili 2 metila ili etila; piridil, izborno supstituiran s fluorom ili klorom; te tienil;
The aqueous pharmaceutical composition for use according to claim 10, 11, 12 or 13, wherein the composition further comprises excipients selected from the group consisting of zinc, m-cresol, glycerol, polysorbate 20 and sodium. 
Farmaceutski pripravak za uporabu prema bilo kojem od zahtjeva 6 do 9, naznačen time da pripravak nadalje sadrži ekscipijente odabrane iz skupine koju čine cink, m-krezol, glicerol, polisorbat 20 i natrij.
reacting the compound of the Formula VII with a suitable chlorinating agent in the presence of a suitable base and a solvent selected from the group consisting of an aryl alkyl ether, a dialkyl ether, a halo substituted benzene and an alkyl substituted benzene, wherein the reaction is carried out by: 
[image] naznačen time, da navedeni postupak obuhvaća: reakciju spoja formule VII sa prikladnim agensom za kloriranje u prisutnosti prikladne baze i prikladnog otapala, gdje se reakcija provodi uz:
With increasing thickness of the second layer the lag time is also increased. 
S povećanjem debljine drugog sloja vrijeme kašnjenja je također raste.
The glove according to claim 13, wherein said vaginal infection is selected from the group consisting of bacterial vaginosis, aerobic vaginitis, fungal infection and viral infection. 
Rukavica u skladu s patentnim zahtjevom 13, naznačena time što se navedena vaginalnu infekcija bira iz skupine koju čine bakterijska vaginoza, aerobni vaginitis, gljivična infekcija i virusna infekcija.
"heterocycloalkyloxy" refers to a (heterocycloalkyl)-O- moiety, where the heterocycloalkyl moiety is attached via a carbon atom to oxygen, wherein the oxygen functions as a linker to attach the moiety to a compound; 
"heterocikloalkiloksi" se odnosi na (heterocikloalkil)-O- ostatak, pri čemu je heterocikloalkilni ostatak vezan preko ugljikovog atoma na kisik, pri čemu kisik funkcionira kao spojnica za spajanje ostatka sa spojem;
The combined ethyl acetate extract was washed with water, dried (MgS04) and evaporated under vacuum to a light brown oil (120 g.), which was crystallized from hexane (91.4 g., 50% yield, m.p. 
Spojeni etilacetatni ekstrakt se ispere s vodom, suši se (MgSOy) i ispari u vakuumu do svijetlomrkog ulja (120 g.), koje se kristalizira iz heksana (92.4 £., 50% prinos, tt.
The term “heterocycloalkyl” as used herein alone or as part of another group refers to alkyl groups as defined above having a heterocyclyl substituent, wherein said heterocyclyl and/or alkyl groups may optionally be substituted as defined above. 
Termin "heterocikloalkil" kao što se ovdje upotrebljava samostalno ili kao dio druge skupine odnosi se na alkilne skupine kao što je gore definirano koje imaju heterociklički supstituent, gdje spomenute heterociklil i/ili alkil skupine mogu biti opcijski supstituirane kao što je gore definirano.